UNSPSC 51334600: Combination lithium salts

This classification denotes combination drugs and preparations that constitute ionic forms of a metal known as lithium, which bears the symbol Li, and atomic number 3, which, in its salt forms, such as lithium carbonate, operates theraputically as a mood stabilizer. Such preparations are therefore LITHIUM SALTS. Typical combination lithium salt constituents are lithium carbonate and sodium chloride.

UNSPSC 51334600 Combination lithium salts is a Class code that in recent state and local procurement practice encompasses pharmaceutical products and drug-management systems far beyond the narrow category name — including naloxone and drug deactivation systems, generic pharmaceuticals and over-the-counter products, and therapeutic pharmacy benefit program administration. State and local jurisdictions and purchasing alliances soliciting under this code span county health departments, state health and human services agencies, and multi-state cooperative purchasing organizations. Work being solicited includes product procurement and logistics (quarterly delivery of naloxone and drug deactivation systems to county health facilities), generic pharmaceutical supply through established wholesaler networks with compliance certification and pricing flexibility, and strategic vendor capacity assessment for direct-to-manufacturer prescription programs designed to improve cost management and fulfillment efficiency outside traditional pharmacy benefit manager channels.

Recent activity concentrates in Florida and the upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, closing July 26, 2023 (note date discrepancy in source), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and two-year initial contract terms. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, closing March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with mandatory supply through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs for self-insured state agencies and employee health plans outside traditional PBM and GPO structures. No explicit set-asides or disadvantaged-enterprise restrictions appear in these solicitations; all require standard compliance certifications (cGMP, DSCSA, E-Verify, drug-free workplace) and insurance coverage.